. Author manuscript; available in PMC: 2019 Jun 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):248–256. doi: 10.1097/QAI.0000000000001666

Table 1.

Demographic and clinical characteristics, and co-morbidities of HIV participants, uninfected volunteers and Alzheimer’s disease group

	HIV+	HIV−	AD	P
N	68	13	24	-
Demographics Age, years	43 (35; 48)	39 (37.5; 52.5)	76.5(67;79.5)	<0.0001
Education, years	8 (5;11)	12 (10.5;16)	4 (2;6)	<0.0001
Gender, n male (%)	33 (49)	10 (77)	8(33)	0.0405
Caucasians, n (%)	66 (97)	13 (100)	22 (92)	0.3688
Clinical
Duration^a,b, months	89 (31; 135)^a	-	36 (24;60)^b	-
MEEM	-	-	14(9.5;20)	-
MoCA, (n=8)			11.5(10.5;12.5)	-
FAQ	-	-	23.5(15;27.5)	-
GDS	0.65 (0.30; 1.05)	0.0(0.0; 0.2)	-	-
Depression	13 (8, 25)^c	-	1(0.5;3)^d	-
Co-morbidities HCV^{e, n} (%)	12 (18)	0	0	-
Log Plasma HCV RNA	2.9 (1.7; 5.9)	0	0	-

Data are median (IQR) or number of cases (%).Participants co-infected with HCV were not on treatment with interferon-gamma. Clinical duration:

of infection on HIV-positive;

of symptoms on AD. Cognitive impairment evaluated by: global deficit score (GDS) on HIV-positive; mini–mental state examination (MMSE); Montreal Cognitive Assessment (MoCA); Functional Activities Questionnaire (Pfeffer’s FAQ) on AD. Major depression disorder (MDD) diagnosed by

Beck depression inventory (BDI) on HIV-positive;

Geriatric Depression scale (GD scale) on AD.

Hepatitis C virus (HCV) status was assessed by antibody testing (Abbott-Architect).